Evolus, Inc. (EOLS): Capital Expenditures
$3.44M
Year ended 2025-12-31
$2.90M
Trailing 12 months to 2026-06-30
+28.6%
3-year compound annual growth
+33.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.44M | +133.8% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $1.47M | +211.2% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $473.0K | -70.8% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $1.62M | +311.7% | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $393.0K | -51.8% | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | $815.0K | +136.2% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $345.0K | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $9.0K | n/a | 2020-02-25, From 2018-01-01 |
| 2017-12-31 | $0 | n/a | 2019-03-20, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | $3.44M | +133.8% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $34.0K | -76.1% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $2.26M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $887.0K | -44.4% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $28.32M | +142.2% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $452.0K | -75.2% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| MannKind Corp (MNKD) | 2025-12-31 | $4.57M | -52.9% |
Compare EOLS, IRWD, CRMD, HROW side by side · Screen every company in Pharmaceutical Preparations ↗